In Nigeria, DMPA-SC—an easy-to-use injectable contraceptive commercially branded as Sayana Press—has been approved for provider- and self-injection, and is being distributed in the public and private sectors. With technical support from the USAID-funded HP+ and the Gates-funded Technical Support Unit, Nigeria’s Federal Ministry of Health applied a new impact model to quantify the potential family planning programmatic impact and cost implications of DMPA-SC introduction and scale-up in Nigeria by 2021. This brief highlights the boost that DMPA-SC can provide to the country’s modern contraceptive prevalence rate, cost savings, and next steps.
Health Policy Plus. 2018. DMPA-SC Introduction and Scale-Up in Nigeria: Future Benefits for Contraceptive Use and Savings. Washington, DC: Palladium, Health Policy Plus.
English PDF 977.5 kbMarch 2018
Information presented on this website is considered public information and may be distributed or copied freely unless identified as being subject to copyright protection.